Long-acting injectable ART: next revolution in HIV?

被引：14
|
作者：
Boyd, Mark A. [1 ,2 ]
Cooper, David A. [2 ]
机构：
[1] Univ Adelaide, Lyell McEwin Hosp, Elizabeth Vale, SA 5112, Australia
[2] Univ New South Wales, Kirby Inst, Sydney, NSW 2052, Australia
来源：
LANCET | 2017年 / 390卷 / 10101期
关键词：
REVERSE-TRANSCRIPTASE INHIBITORS; INFECTED PATIENTS; NAIVE ADULTS; DOUBLE-BLIND; TRIAL; THERAPY;
D O I：
10.1016/S0140-6736(17)31962-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1468 / 1470
页数：4
相关论文
共 50 条
  • [31] Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy
    Young, Isabella C.
    Pallerla, Aryani
    Cottrell, Mackenzie L.
    Maturavongsadit, Panita
    Prasher, Alka
    Shrivastava, Roopali
    Cruz, Gabriela De la
    Montgomery, Stephanie A.
    Schauer, Amanda
    Sykes, Craig
    Kashuba, Angela D. M.
    Benhabbour, S. Rahima
    JOURNAL OF CONTROLLED RELEASE, 2023, 363 : 606 - 620
  • [32] Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis
    Prather, Caitlin
    Jeon, Chaeok
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (21) : 1898 - 1905
  • [33] Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges
    Christopoulos, Katerina A.
    Hickey, Matthew D.
    Rana, Aadia
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (01) : 11 - 18
  • [34] Long-acting injectable antiretroviral therapy for HIV-1 infection in adults
    Halani, Sheliza
    Tan, Darrell
    Andany, Nisha
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (10) : E341 - E342
  • [35] Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon, Geoffroy
    Ghosn, Jade
    HIV MEDICINE, 2023, 24 (06) : 653 - 663
  • [36] Expectations and acceptability of long-acting injectable antiretrovirals by patients living with HIV/AIDS
    Palacios, Christia
    Wilpotte, Celine
    Adda, Anne
    Allaf, Salima
    Thibaut, Peline
    Chas, Julie
    Siguier, Martin
    Pialoux, Gilles
    INFECTIOUS DISEASES NOW, 2022, 52 (04): : 238 - 239
  • [37] EVIDENCE FOR THE USE OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS
    Amladi, Anjani
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S44 - S44
  • [38] Long-Acting Injectable Antipsychotics: Recommendations for Clinicians
    Malla, Ashok
    Tibbo, Phil
    Chue, Pierre
    Levy, Emmanuelle
    Manchanda, Rahul
    Teehan, Michael
    Williams, Richard
    Iyer, Srividya
    Roy, Marc-Andre
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2013, 58 (05): : 30S - 35S
  • [39] The relevance of TDM for long-acting injectable antipsychotics
    Schoretsanitis, G.
    PHARMACOPSYCHIATRY, 2022, 55 (03) : 168 - 169
  • [40] Long-acting injectable risperidone: Efficacy and safety
    Kane, JM
    Eerdekens, M
    Keith, SJ
    Lesem, M
    Karcher, K
    Lindenmayer, JP
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S325 - S325
12345